Phase 2a proof-of-concept study of PXL770 in patients with type-2 diabetes mellitus

Trial Profile

Phase 2a proof-of-concept study of PXL770 in patients with type-2 diabetes mellitus

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs PXL 770 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2017 According to Poxel media release, company is planning to initiate this study in 2018.
    • 29 Jul 2016 New trial record
    • 12 Jul 2016 According to Poxel media release, this trial is expected to be conducted in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top